United Therapeutics chairperson & CEO sells $5.08m in shares

Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp (NASDAQ:UTHR), sold common stock totaling approximately \$5.08 million on October 16, 2026. The transactions were executed at prices ranging from \$530.4754 to \$543.85 per share. The stock currently trades at $543.15, with InvestingPro analysis suggesting the shares are overvalued relative to its Fair Value estimate.

The sale involved 9,000 shares of common stock, which followed the exercise of 9,500 stock options at an exercise price of \$117.76 per share, totaling approximately \$1.12 million. Both the option exercise and the subsequent sale of shares were conducted under a pre-arranged 10b5-1 trading plan. This plan was adopted by Ms. Rothblatt on November 7, 2025, and is set to continue until either 1,734,410 stock options are exercised (all of which expire on March 15, 2027) or December 31, 2026, whichever comes first. The stock options exercised on this date vested in equal one-third installments on March 15, 2021, 2022, and 2023. The company maintains a "GREAT" financial health score according to InvestingPro, with a market capitalization of $23.35 billion.

Following these transactions, Ms. Rothblatt’s beneficial ownership in United Therapeutics includes 324,443 shares held indirectly by a family trust where she shares investment power. Additional holdings include 40,513 shares held directly, 166 shares indirectly by a spouse, 249,108 shares indirectly by family trusts where her spouse is a trustee, 45,596 shares indirectly by family trusts where her spouse shares investment power, and 8,902 shares indirectly by family trusts where she is the sole trustee. Ms. Rothblatt also holds 214,410 stock options indirectly through a family trust.

In other recent news, United Therapeutics reported a revenue miss of approximately 3% in its second-quarter results, prompting BofA Securities to lower its price target from $613 to $559 while maintaining a Neutral rating. Additionally, United Therapeutics reached a settlement agreement with Liquidia Technologies, resolving all litigation between the companies. As part of the settlement, Liquidia agreed to pay United Therapeutics $380.7 million and make adjustments to the YUTREPIA label, which will now only be available for pulmonary arterial hypertension.

Jefferies responded to the settlement by raising its price target for United Therapeutics to $728, maintaining a Buy rating. Following a favorable patent ruling related to its Tyvaso franchise, Cantor Fitzgerald reiterated an Overweight rating with a $700 price target. BTIG upgraded United Therapeutics to Buy from Neutral, citing the patent decision as a significant impediment to competitor Liquidia’s Yutrepia product.

Conversely, Goldman Sachs initiated coverage with a Sell rating and a price target of $321, noting concerns about United Therapeutics’ price-to-earnings ratio and a declining base business. These developments highlight varied analyst perspectives on United Therapeutics’ future prospects.